Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Castration-Resistant Prostate Cancer
NCT04754425Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erdafitinib in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2021; status: terminated.
02
Drugs
erdafitinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04754425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754425.